A feedback loop of PPP and PI3K/AKT signal pathway drives regorafenib-resistance in HCC.

ABSTRACT:

Background

Hepatocellular carcinoma (HCC) is a principal type of liver cancer with high incidence and mortality rates. Regorafenib is a novel oral multikinase inhibitor for second-line therapy for advanced HCC. However, resistance to regorafenib is gradually becoming a dilemma for HCC and the mechanism remains unclear. In this study, we aimed to reveal the metabolic profiles of regorafenib-resistant cells and the key role and mechanism of the most relevant metabolic pathway in regorafenib resistance.

Methods

Metabolomics was performed to detect the metabolic alteration between drug-sensitive and regorafenib-resistant cells. Colony formation assay, CCK-8 assay and flow cytometry were applied to observe cell colony formation, cell proliferation and apoptosis, respectively. The

SUBMITTER: Yang H 

PROVIDER: S-EPMC10726576 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature